Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells

Drug Des Devel Ther. 2022 Jun 27:16:1963-1974. doi: 10.2147/DDDT.S367586. eCollection 2022.

Abstract

Introduction: Numerous drugs with potent toxicity against cancer cells are available for treating malignancies, but therapeutic efficacies are limited due to their inefficient tumor targeting and deleterious effects on non-cancerous tissue. Therefore, two improvements are mandatory for improved chemotherapy 1) novel delivery techniques that can target cancer cells to deliver anticancer drugs and 2) methods to specifically enhance drug efficacy within tumors. The loading of inert drug carriers with anticancer agents and peptides which are able to bind (target) tumor-related proteins to enhance tumor drug accumulation and local cytotoxicity is a most promising approach.

Objective: To evaluate the anticancer efficacy of Chitosan nanoparticles loaded with human growth hormone hGH fragment 176-191 peptide plus the clinical chemotherapeutic doxorubicin in comparison with Chitosan loaded with doxorubicin alone.

Methods: Two sets of in silico experiments were performed using molecular docking simulations to determine the influence of hGH fragment 176-191 peptide on the anticancer efficacy of doxorubicin 1) the binding affinities of hGH fragment 176-191 peptide to the breast cancer receptors, 2) the effects of hGH fragment 176-191 peptide binding on doxorubicin binding to these same receptors. Further, the influence of hGH fragment 176-191 peptide on the anticancer efficacy of doxorubicin was validated using viability assay in Human MCF-7 breast cancer cells.

Results: In silico analysis suggested that addition of the hGH fragment to doxorubicin-loaded Chitosan nanoparticles can enhance doxorubicin binding to multiple breast cancer protein targets, while photon correlation spectroscopy revealed that the synthesized dual-loaded Chitosan nanoparticles possess clinically favorable particle size, polydispersity index, as well as zeta potential.

Conclusion: These dual-loaded Chitosan nanoparticles demonstrated greater anti-proliferative activity against a breast cancer cell line (MCF-7) than doxorubicin-loaded Chitosan. This dual-loading strategy may enhance the anticancer potency of doxorubicin and reduce the clinical side effects associated with non-target tissue exposure.

Keywords: anticancer potency; cytotoxicity; docking analysis; nanoparticles.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Breast Neoplasms* / drug therapy
  • Chitosan* / chemistry
  • Chitosan* / pharmacology
  • Doxorubicin
  • Female
  • Human Growth Hormone*
  • Humans
  • MCF-7 Cells
  • Molecular Docking Simulation
  • Nanoparticles* / chemistry
  • Peptides / therapeutic use

Substances

  • Antineoplastic Agents
  • Peptides
  • Human Growth Hormone
  • Doxorubicin
  • Chitosan

Grants and funding

This research was funded by the Deanship of Scientific Research, Jazan University, Jazan, Saudi Arabia; grant number JUP8/318.